Perioperative and palliative systemic treatments for biliary tract cancer.

Ther Adv Med Oncol · 2024 · PMC10981863 · PMID 38559612

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

An mOS showed a trend toward improvement with Ivosidenib, but it was not statistically significant (10.3 versus 7.5 months, HR 0.79).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.